Organon & Co. (NYSE: OGN) Acquisition: Shareholder Value Under Scrutiny

• Organon & Co. (NYSE: OGN), a global healthcare company focused on women's health, recently received an analyst upgrade to Neutral with a $14.00 price target.
• India's Sun Pharmaceutical Industries plans to acquire Organon for $14.00 per share in an all-cash deal, valuing the transaction at approximately $11.75 billion.
• The acquisition is currently under scrutiny by law firms investigating whether Organon's board secured the best possible price for shareholders.

Organon & Co. (NYSE: OGN) is a global healthcare company that develops and delivers medicines and solutions for women's health. Spun off from Merck in 2021, the company's portfolio covers reproductive health, contraception, and other health areas. It operates in a competitive pharmaceutical landscape, focusing on a specialized and growing market segment.

An analyst at Piper Sandler is upgrading Organon to a Neutral rating from a previous Underweight status. This change in outlook comes with a new price target of $14.00 per share. At the time of the announcement, the stock was trading at a price of $13.18.

This price target aligns with a major corporate development. As highlighted by Zacks, India's Sun Pharmaceutical Industries announced it will acquire Organon for $14.00 per share in an all-cash deal. The news caused Organon shares to jump approximately 16% in pre-market trading, reflecting investor reaction to the buyout price.

The acquisition gives the transaction an enterprise value of around $11.75 billion and is a strategic move for Sun Pharma. It aims to expand its presence in biosimilars, which are biologic medical products highly similar to another already approved biological medicine. This deal also increases its scale in the global women's health market.

However, the deal is under scrutiny. Law firms like Johnson Fistel, PLLP and Halper Sadeh LLC are investigating Organon's board, as reported by GlobeNewswire and Business Wire. The investigations question if the board fulfilled its duties to get the best possible price for shareholders, suggesting the $14.00 offer may undervalue the company.